Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 5/20 | 0.37 |
| ▸ | CNR2 | P34972 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CBLB | Q13191 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25136099 | 0.80 | ABL1 (0.39) | CNR2KDM4EGLAHTTKMT2A | |
| SCHEMBL25135909 | 0.80 | ABL1 (0.39) | CNR2KDM4EGLAHTTKMT2A | |
| SCHEMBL25136301 | 0.80 | CBLB (0.40) | HTTCBLBGRM5 | |
| SCHEMBL25136211 | 0.80 | CBLB (0.40) | HTTCBLBGRM5 | |
| SCHEMBL25136213 | 0.80 | CNR2 (0.33) | CNR2CBLBGRM5DEGS1ABL1 | |
| SCHEMBL25135921 | 0.80 | CNR2 (0.38) | CNR2KDM4EGLAHTTKMT2A | |
| SCHEMBL25136058 | 0.80 | CNR2 (0.33) | CNR2CBLBGRM5DEGS1ABL1 | |
| SCHEMBL25136101 | 0.79 | PIM1 (0.37) | CNR2KDM4EGLAHTTKMT2A | |
| SCHEMBL25136129 | 0.79 | KMO (0.37) | CNR2CBLBABL1 | |
| SCHEMBL25136085 | 0.79 | KMO (0.37) | CNR2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885CNR2 547/4885KDM4E 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.